Component

Human verbal-learning response in ergothioneine MCI pilot

Context-specific entity; species, compartment and exposure are stated on each claim.

1 recorded relationships. Experimental role, claim status and evidence remain attached to each record.

How nutrients influence it

Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.

How nutrients reach it in more than one step

Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.

Tracing routes…

What it does

Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.

Recorded relationships

What acts on it

  1. A 19-person randomized MCI pilot reported improved verbal-learning performance with 25 mg ergothioneine three times weekly for one year.

    Experimental context and source evidence
    evidence_access
    Primary abstract
    experimental_model
    Double-blind placebo-controlled pilot; adults at least 60 years old.
    limitations
    Small trial, not established dementia prevention; blood safety markers cannot exclude uncommon adverse effects.
    nutrient_topic
    Ergothioneine collection; molecular form, preparation, species, exposure and manipulation remain explicit. · L-Ergothioneine
    plain_language
    A small human trial found a preliminary cognitive signal.
    primary_references
    Investigating the efficacy of ergothioneine to delay cognitive decline in mild cognitively impaired subjects: A pilot study. · 2024 · https://pubmed.ncbi.nlm.nih.gov/39544014/ · DOI 10.1177/13872877241291253

    Ergothioneine: transport, redox chemistry and cross-nutrient mechanisms (2026-09-19) · lines 496–502

    AI-assisted research curation; primary references, access levels and experimental limitations individually identified. Not publisher full text. · supports · Double-blind placebo-controlled pilot; adults at least 60 years old. · source_derived_draft · unverified_draft

    ## ergothioneine-mci-pilot A small human trial found a preliminary cognitive signal. A 19-person randomized MCI pilot reported improved verbal-learning performance with 25 mg ergothioneine three times weekly for one year. Model: Double-blind placebo-controlled pilot; adults at least 60 years old. Limitations: Small trial, not established dementia prevention; blood safety markers cannot exclude uncommon adverse effects. Evidence access: Primary abstract Investigating the efficacy of ergothioneine to delay cognitive decline in mild cognitively impaired subjects: A pilot study. · 2024 · https://pubmed.ncbi.nlm.nih.gov/39544014/ · DOI 10.1177/13872877241291253
    Complete structured claim and evidence

In the sources

Preserved passages that mention this component, quoted exactly. Open one to read it in context.

    This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.

    Evidence, AI assistance and curation standards